In patients with metabolic-associated steatotic liver disease or metabolic-associated steatohepatitis, resmetirom and ...

Guangdong Zhongsheng Ruichuang Pharmaceutical Co. Ltd. has described glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 2 diabetes, obesity, ...

Furthermore, mazdutide, the fastest-developing dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist globally, has ignited significant research interest in the scientific community ...

Altimmune Inc. advanced stock charts by Barron's. View ALT historical stock data and compare to other stocks, and exchanges.

For instance, glucagon-like peptide-1 (GLP-1) receptor agonists, which have made waves as therapies for diabetes and obesity, appear to hold promise for patients with MASLD and MASH, the authors said.

Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors can improve liver-related biomarkers, their ability to reduce the risks for NAFLD ...

Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024 ...

Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors can improve liver-related biomarkers, their ability to reduce the risks for ...

Preclinical studies and large-scale randomized controlled trials have demonstrated that glucagon-like peptide 1 receptor agonists (GLP-1RAs) can improve hepatic steatosis, balloon degeneration, and ...

Like those drugs, survodutide activates an insulin-regulating hormone called GLP-1. But the drug also targets a receptor controlling the hormone glucagon, which could be useful for treating MASH ...